EA200400482A1 - Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран - Google Patents

Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран

Info

Publication number
EA200400482A1
EA200400482A1 EA200400482A EA200400482A EA200400482A1 EA 200400482 A1 EA200400482 A1 EA 200400482A1 EA 200400482 A EA200400482 A EA 200400482A EA 200400482 A EA200400482 A EA 200400482A EA 200400482 A1 EA200400482 A1 EA 200400482A1
Authority
EA
Eurasian Patent Office
Prior art keywords
keratinocyces
ras
treatment
application
active substance
Prior art date
Application number
EA200400482A
Other languages
English (en)
Other versions
EA009073B1 (ru
Inventor
Петра Эберхардт
Вольфганг Нё
Катарина Райф
Original Assignee
Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг filed Critical Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг
Publication of EA200400482A1 publication Critical patent/EA200400482A1/ru
Publication of EA009073B1 publication Critical patent/EA009073B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/395—Thyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В заявке описаны новые культивируемые in vitro кератиноциты, а также их предпочтительное применение для получения продукта, который может использоваться для лечения свежих и перешедших в хроническую форму ран.Отчет о международном поиске был опубликован 2004.02.12.
EA200400482A 2001-10-17 2002-10-14 Препарат выделенных кератиноцитов, носитель, покрытый этими клетками, способ криоконсервации препарата и способ лечения ран EA009073B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10151296A DE10151296A1 (de) 2001-10-17 2001-10-17 Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden
PCT/EP2002/011459 WO2003033686A2 (de) 2001-10-17 2002-10-14 Keratinozyten verwendbar als biologisch aktive substanz bei der behandlung von wunden

Publications (2)

Publication Number Publication Date
EA200400482A1 true EA200400482A1 (ru) 2004-12-30
EA009073B1 EA009073B1 (ru) 2007-10-26

Family

ID=7702826

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200400482A EA009073B1 (ru) 2001-10-17 2002-10-14 Препарат выделенных кератиноцитов, носитель, покрытый этими клетками, способ криоконсервации препарата и способ лечения ран

Country Status (30)

Country Link
US (3) US7247478B2 (ru)
EP (1) EP1440148B1 (ru)
JP (1) JP4476625B2 (ru)
KR (1) KR101019916B1 (ru)
CN (1) CN100432220C (ru)
AR (1) AR036827A1 (ru)
AT (1) ATE474039T1 (ru)
AU (1) AU2002349352B2 (ru)
BR (1) BR0213282A (ru)
CA (1) CA2461141C (ru)
CO (1) CO5580844A2 (ru)
DE (2) DE10151296A1 (ru)
DK (1) DK1440148T3 (ru)
EA (1) EA009073B1 (ru)
EC (1) ECSP045065A (ru)
ES (1) ES2345767T3 (ru)
HR (1) HRP20040347B1 (ru)
HU (1) HU228887B1 (ru)
IL (2) IL161442A0 (ru)
MX (1) MXPA04003487A (ru)
MY (1) MY137828A (ru)
NO (1) NO334974B1 (ru)
NZ (1) NZ532899A (ru)
PE (1) PE20030627A1 (ru)
PL (1) PL367338A1 (ru)
RS (1) RS30104A (ru)
UA (1) UA81398C2 (ru)
UY (1) UY27486A1 (ru)
WO (1) WO2003033686A2 (ru)
ZA (1) ZA200402306B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
AU2004262002B2 (en) * 2003-08-01 2010-03-25 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
WO2006010161A2 (en) * 2004-07-20 2006-01-26 The Regents Of The University Of California In vitro wound healing assay and device
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
AU2008311813B2 (en) * 2007-10-19 2012-01-12 Biointraface, Inc. Novel compositions and related methods, coatings, and articles
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
AU2009252722A1 (en) 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN107011345A (zh) 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
WO2011154402A1 (en) * 2010-06-09 2011-12-15 Chanel Parfums Beaute Inhibitors of micro-rnas for use for preventing and/or attenuating skin ageing and/or for hydrating skin
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PL2731947T3 (pl) 2011-07-15 2019-07-31 Boehringer Ingelheim International Gmbh Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP2854824A1 (en) * 2012-05-25 2015-04-08 Boehringer Ingelheim International GmbH Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN105219697A (zh) * 2014-07-04 2016-01-06 赫柏慧康生物科技无锡有限公司 一种人原代角质细胞分离制备的方法
EP3132809A1 (en) 2015-08-21 2017-02-22 Bioskinco GmbH Composition and products comprising senescent cells for use in tissue regeneration
US10668259B2 (en) 2015-10-21 2020-06-02 Materials Science Associates, LLC Metal oxide and polymer controlled delivery systems, sunscreens, treatments, and topical coating applicators
US11484816B2 (en) * 2016-04-12 2022-11-01 Unicyte Ev Ag Isolation of extracellular vesicles (EVs) from biological fluid samples
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN109055303A (zh) * 2018-09-12 2018-12-21 山东麦德克斯生物科技有限公司 一种皮肤组织的构建方法
RU2731065C1 (ru) * 2019-12-24 2020-08-28 Федеральное государственное бюджетное учреждение науки Институт биологии развития им. Н.К. Кольцова РАН (ИБР РАН) Состав криоконсерванта для длительного хранения первичных кератиноцитов

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016038A (en) * 1968-04-01 1977-04-05 Hayashibara Company Process for preparing maltoses from starches
US4016036A (en) 1975-11-14 1977-04-05 Massachusetts Institute Of Technology Process for serially culturing keratinocytes
IT1207525B (it) 1987-06-23 1989-05-25 Ist Naz Ric Sul Cancro Metodo per la preservazione difogli trapiantabili di epitelio coltivato in vitro vitale.
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
IT1248934B (it) 1990-06-01 1995-02-11 Fidia Spa Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle
US6126935A (en) 1991-11-20 2000-10-03 N.V. Innogenetics S.A. Pellets obtained from cell cultures of keratinocytes and their use in wound healing
US6585969B1 (en) 1991-11-20 2003-07-01 N. V. Innogenetics S.A. Non-viable keratinocyte cell composition or lysate for promoting wound healing
US5518878A (en) 1993-09-15 1996-05-21 Organogenesis Inc. Cryopreservation of cultured skin or cornea equivalents with agitation
US5891617A (en) 1993-09-15 1999-04-06 Organogenesis Inc. Cryopreservation of harvested skin and cultured skin or cornea equivalents by slow freezing
US5693332C1 (en) 1995-08-11 2001-01-09 Univ California Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
AUPP244498A0 (en) 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
DE19917532A1 (de) 1999-04-19 2000-10-26 Christian Toloczyki Trägergebundene kultivierte Stamm-bzw. Vorläuferzellen von Keratinozyten

Also Published As

Publication number Publication date
KR101019916B1 (ko) 2011-03-08
DK1440148T3 (da) 2010-09-27
MY137828A (en) 2009-03-31
RS30104A (en) 2006-10-27
JP2005505392A (ja) 2005-02-24
US7247478B2 (en) 2007-07-24
IL161442A (en) 2012-02-29
HUP0600341A2 (en) 2006-08-28
EA009073B1 (ru) 2007-10-26
PE20030627A1 (es) 2003-07-16
ES2345767T3 (es) 2010-10-01
DE10151296A1 (de) 2003-04-30
HRP20040347A2 (en) 2005-04-30
UA81398C2 (en) 2008-01-10
CN100432220C (zh) 2008-11-12
IL161442A0 (en) 2004-09-27
CO5580844A2 (es) 2005-11-30
UY27486A1 (es) 2003-05-30
ECSP045065A (es) 2004-05-28
US20030091542A1 (en) 2003-05-15
MXPA04003487A (es) 2004-07-30
NO334974B1 (no) 2014-08-11
AR036827A1 (es) 2004-10-06
WO2003033686A3 (de) 2004-02-12
US7754481B2 (en) 2010-07-13
ZA200402306B (en) 2006-05-31
US20080131967A1 (en) 2008-06-05
AU2002349352B2 (en) 2007-11-01
PL367338A1 (en) 2005-02-21
WO2003033686A2 (de) 2003-04-24
CA2461141C (en) 2011-12-06
CA2461141A1 (en) 2003-04-24
KR20040045856A (ko) 2004-06-02
NO20041570L (no) 2004-04-16
HU228887B1 (hu) 2013-06-28
CN1571835A (zh) 2005-01-26
HUP0600341A3 (en) 2011-03-28
US7306943B2 (en) 2007-12-11
JP4476625B2 (ja) 2010-06-09
ATE474039T1 (de) 2010-07-15
DE50214540D1 (de) 2010-08-26
BR0213282A (pt) 2004-10-26
EP1440148B1 (de) 2010-07-14
EP1440148A2 (de) 2004-07-28
HRP20040347B1 (en) 2012-07-31
NZ532899A (en) 2006-04-28
US20070065419A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
EA200400482A1 (ru) Кератиноциты, пригодные для применения в качестве биологически активной субстанции при лечении ран
DE60236413D1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
EA200201214A1 (ru) Замещенные тиоацетамиды
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
CY1111386T1 (el) Ενωσεις και μεθοδοι για αυξηση νευρογενεσης
EA200200990A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы дельта человека
EA200300929A1 (ru) Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
FI970747A (fi) Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE69829202D1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
EA200200948A1 (ru) Лечение псориаза
ATE281165T1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
EA200500765A1 (ru) Применение докозагексановой кислоты в качестве активного вещества для лечения липодистрофии
ATE545421T1 (de) Pharmazeutisches präparat zur behandlung von parasitären tropenkrankheiten enthaltend diminazen-di-aceturat
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU